Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Radiation Fibrosis Syndrome 2Pancreatic Neoplasms 2Pancreatic Adenocarcinoma 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Ductal Adenocarcinoma 1Osteosarcoma 1Neuroma, Acoustic 1Inflammation 1Fibrosis 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Camurati-Engelmann Syndrome 1

Interventions

pembrolizumab 139Cisplatin 76Cetuximab 53Carboplatin 49Paclitaxel 39Nivolumab 39Radiotherapy 37Docetaxel 34Radiotherapy, Intensity-Modulated 30Magnetic Resonance Spectroscopy 25Specimen Handling 20Fluorouracil 20Platinum 141,2-diaminocyclohexaneplatinum II citrate 13Taxes 12cemiplimab 11Radiation 11Ipilimumab 11atezolizumab 10Surgical Procedures, Operative 10Drug Therapy 10tislelizumab 9Biopsy 9durvalumab 8Radiosurgery 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8Standard of Care 7Chemoradiotherapy 7Immune Checkpoint Inhibitors 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × Losartan × 1 year × Clear all
NCT06211335 2026-03-12

Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma

University of California, Davis

Phase 1 Recruiting
24 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡